Morgan Stanley lowered the firm’s price target on Humana (HUM) to $624 from $637 and keeps an Overweight rating on the shares. With Q2 earnings season now behind, the firm believes cost trend concerns have “significantly subsided,” helping to create a cleaner path forward to owning Managed Care stocks and grows increasingly positive on Elevance (ELV), its “Top Pick,” Humana and Alignment Healthcare (ALHC), the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on HUM:
- Jefferies healthcare analysts to hold an analyst/industry conference call
- Humana announces agreement with Interwell Health
- Humana price target lowered to $613 from $616 at TD Cowen
- Starboard takes stake in Algonquin Power, exits position in Enovis
- Humana price target raised to $599 from $568 at Bernstein